50 results about "Angioma" patented technology

Provided herein is a poly(ester amide) (PEA) polymer blend and a polymeric coating containing the PEA polymer blend. The PEA polymer blend has a Tg above the Tg of poly(ester amide benzyl ester) (PEA-Bz) or the Tg of poly(ester amide TEMPO). The PEA polymer blend can form a coating on an implantable device, one example of which is a stent. The coating can optionally include a biobeneficial material and / or optionally with a bioactive agent. The implantable device can be used to treat or prevent a disorder such as one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

Provided herein is a PEA polymer blend and coatings or implantable devices formed therefrom. The PEA polymer blend is formed of a PEA polymer and a material capable of hydrogen bonding with the PEA. The PEA polymer blend can form a coating on an implantable device, one example of which is a stent. The coating can optionally include a biobeneficial material and / or optionally with a bioactive agent. The implantable device can be used to treat or prevent a disorder such as one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

The invention discloses a classifier for micro-angioma of diabetes lesion based on a colored image. The classifier comprises an image pre-processing subsystem, a multi-size multi-directional matching filter, a regional growth subsystem, a characteristic quantity extraction system and a classification subsystem, wherein the image pre-processing subsystem reduces noise of a retina image of a candidate, the filter positions the micro-angioma in the retina image, the regional growth subsystem restores the size and shape of the micro-angioma in the retina image, the characteristic quantity extraction system extracts 37-dimensional characteristic of the micro-angioma in the retina image, and the classification subsystem classifies the candidate based on a support vector machine; and the output end of the image pre-processing subsystem is connected with the input end of the classification subsystem via the multi-size multi-directional matching filter, the regional growth subsystem and the characteristic quantity extraction system. The classifier can effectively identify the micro-angioma in the retina image.

A composition and method having anti-aging properties is provided. The composition comprises an arNOX inhibitory agent present in a natural plant extract and is useful topically as a cosmetic. The symptoms of aging including lines, wrinkles, hyperpigmentation, dehydration, loss of elasticity, angioma, dryness, itching, telangietasias, actinic purpura, seborrheic keratoses and actinic keratoses. The invention may be used multiple times a day without deleterious effects.

Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

Disclosed are compounds which are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

The invention relates to the field of medicines, in particular to an angiogenesis inhibitor for inhibiting several matrix metal protein enzyme and inhibiting the transfer of the vascular endothelial cell, which can be applied to preparation and treatment of entity tumor and rheumatoid arthritis. The polypeptide comprises a polypeptide I, polypeptide II, polypeptide III and polypeptide IV (Seq NO.1, Seq NO.2, Seq NO.3, Seq NO.4); The polypeptide can be used for treating entity tumor and rheumatoid arthritis. The four angiogenesis inhibitors can be applied to preparation of medicine for treating tumor, and is characterized in that: the tumor is derived from primary of neck, brain, thyroid gland, esophagus, pancreas, lung, liver, stomach, mammary gland, kidney, colon or rectum, ovary, cervix, uterus, prostate, bladder and testis or secondary cancer, melanoma, hemangioma and sarcoma.

The invention relates to the field of medicines, and in particular relates to an inhibitor of angiogenesis capable of inhibiting matrix metallo-proteinase and migration of vascular endothelial cells. The inhibitor can be used for preventing and treating solid tumor and rheumatoid arthritis. The polypeptide specifically means polypeptide I, polypeptide II, polypeptide III and polypeptide IV (with reference to SeqNO.1, SeqNO.2, SeqNO.3 and SeqNO.4). The polypeptide can be used for treating solid tumor and rheumatoid arthritis. The four inhibitors of angiogenesis can be applied to preparing medicines for treating tumor. The polypeptide is characterized in that tumor is originated from essential or subsequent cancers, melanoma, hemangioma and sarcoma of heat and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gall bladder, colon or rectum, ovary, cervix uterus, uterus, prostate, bladder and testis.

The invention discloses a method for identifying and detecting encephalofacial angiomatosis image on a basis of skeleton characteristics. The method comprises the following steps: (1) performing binaryzation to a gray level image; (2) extracting a skeleton tree and obtaining a single-pixel curve image; (3) extracting a skeleton structure unit, wherein a key point unit is a branch point and an endpoint in the skeleton tree image; a branch unit is a skeleton section which connects two key point units but does not pass through a third key point, wherein at least one of the two key point units is a unit of an endpoint and is an external branch unit; and (4) determining thresholds T1 and T2, wherein the length of the external branch unit to be detected is S; and judging the encephalofacial angiomatosis image according to the relationship between S and T1 as well as T2, wherein T1 is an integer ranging between 6 to 10 and T2 is an integer ranging between 14 to 18. Due to the adoption of the method of the invention, time complexity of arithmetic is low, the result is precise, and good assistance can be provided for a doctor to diagnose the encephalofacial angiomatosis.

Disclosed are compounds of the formula: wherein the formula variables are as defined herein. The compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase. Also disclosed is the use of such compounds in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.

Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.

The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.

The invention relates to a decapeptide inhibiting angiogenesis and use thereof, belonging to the technical field of biological medicine. The decapeptide inhibiting angiogenesis provided by the invention is deprived from human Homo sapien with an amino acid sequence of YNWNSFGLRF and the molecular weight of 1303.4, and is named as Kp-10. The invention further provides use of the decapeptide inhibiting angiogenesis for preparing medicines for inhibition of angiogenesis, in particular relevant use of Kp-10 for preparing medicines for inhibition of angiogenesis dependent diseases such as cancer, rheumatoid arthritis, psoriasis, diabetes syndrome, and hemangioma. A series of experimental results in VEGF (Vascular Endothelial Growth Factor) induction shows that Kp-10 has obvious inhibition function in the proliferation experiment of human umbilical vein endothelial cells (HUVEC), transfer experiment, micro-tube forming experiment, angiogenesis experiment of chick embryo allantois and mouse cornea experiment, and the decapetide can be used for preparing medicines for inhibiting angiogenesis.

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

A polymer of hydrophobic monomers and hydrophilic monomers is provided. It is also provided a polymer blend that contains the polymer and another biocompatible polymer. The polymer or polymer blend and optionally a biobeneficial material and / or a bioactive agent can form a coating on an implantable device such as a drug delivery stent. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

The removable spring ring for treating angioma belongs to the field of angioma treating technology and medical equipment technology. The removable spring ring for treating angioma includes one spring ring with one coating of biodegradable polymer, hydro gel or medicine for efficient embolism, and one conveying duct connected to the spring ring via insulating polymer adhesive. The polymer coating in the spring ring can speed the formation of coagulated tissue inside the angioma to embolize and has controllable degrading speed; the hydro gel can expand in blood or moisture condition for dealing with giant aneurysm; and the medicine for efficient embolism can raise the treatment effect.

Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and / or a bioactive agent. The coating composition can form a coating on an implantable device. The implantable device can be used to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

The invention relates to a composition of timolol or a salt of the timolol, hydrogel emplastrum of the composition, and a purpose for treating angioma, in particular to timclol maleate hydrogel emplastrum used for treating infant angioma. The composition of the timolol or the salt of the timolol comprises a stabilizer to improve the light stability of a medicinal preparation of the timolol or thesalt of the timolol. The hydrogel emplastrum of the timolol or the salt of the timolol comprises the timolol or the salt of the timolol, particularly maleate, the stabilizer, a high-molecular polymer,a wetting agent, a cross-linking agent, a cross-linking conditioning agent, a pH value conditioning agent (appropriate amount is 2-8), a viscosity conditioning agent, a preservative, a filling agentand purified water. The composition and the preparation disclosed by the invention have good light stability, viscosity and a comfort level, and medicines slowly and smoothly release so as to prolongmedicine acting time. The hydrogel emplastrum can be repeatedly uncovered and pasted, does not irritate skin, is convenient in use, has a long-lasting effect, is high in stability, has a simple production technology, is suitable for industrial production and is free from "three wastes (industrial wastewater, waste gases and residues)".

The present invention transplants hemangioma endothelial cell and tumor cell or tumor cell releasing product isolating cultured from human hemangioma structure, to immunologic deficiency mouse hypodermic, to obtain human hemangioma mouse animal model. The present invented technology method is portably in technical operation and with high model success ratio, the experimental evidence proving that said blood vessel endothelial cell in hemangioma model established is human hemangioma endothelial cell, and said model having the pathology property of human angiomatous intumescentia blood sinus and rebirth capillary vessel. Said hemangioma animal model can be used in system researching angiomatous pathogenesis screening human angiomatous therapeutic drug.

The inhibitor of angiogenesis is characterized by containing tetraacetylphytosphingosine and the kit for inhibiting angiogenesis is characterized by the inhibitor. The inhibitor and kit are effective in treating and preventing disorders in connection with extremely increased angiogenesis such as angioma, tumor and psoriasis by effectively inhibiting angiogenesis. Furthermore, they are effective in inhibiting proliferation of cancer cells and metastasis of cancer without any adverse effect.

The invention relates to application of platycodin D in preparation of medicines for preventing and treating pulmonary hypertension. According to the technical scheme, platycodin D and compositions containing platycodin D are used for treating pulmonary hypertension and cardiovascular related diseases caused by pulmonary hypertension. Experimental researches discover that platycodin D can be used for preventing and treating arbitrary one or more of idiopathic pulmonary hypertension, heritable pulmonary arterial hypertension, drug and toxin related pulmonary hypertension, hazard factor or disease related pulmonary hypertension, pulmonary hypertension caused by pulmonary veno-occlusive disease and (or) pulmonary capillary hemangiomatosis-like diseases, and persistent pulmonary hypertension of newborn.

The invention relates to a preparation method of saponin of radix adenophorae as well as an application of the saponin of radix adenophorae, which is prepared in accordance with technical scheme of the invention, in treating medicines for treating pulmonary arterial hypertension and related cardiovascular diseases caused by the pulmonary arterial hypertension. Based upon experimental studies, the saponin of radix adenophorae provided by the invention can take an obvious effect on reducing mean pulmonary arterial pressure (MPAP), right ventricle systolic pressure (RVSP) and right ventricular hypertrophy index (RVHI) of the pulmonary arterial hypertension. The saponin of radix adenophorae can be used for preventing and treating one or more diseases of special pulmonary arterial hypertension, heritable pulmonary arterial hypertension, drug and poison related pulmonary arterial hypertension, risk factor or disease related pulmonary arterial hypertension, pulmonary arterial hypertension caused by pulmonary veno-occlusive disease and (or) pulmonarycapillary hemangiomatosis, and neonatal persistent pulmonary arterial hypertension.

The invention relates to a Chinese medicinal composition for treating ocular fundus vascular diseases, belonging to the medical field. A Chinese medicinal composition is prepared from Astragalus membranaceus, honeysuckle, cortex phellodendron, atractylodes atractylodes, radix scrophulariae, angelica sinensis, radix paeoniae alba andcoix seed. As proved by pharmacodynamics and clinical trials, thatcomposition of the invention can improve the phenomenon of retinal hemorrhage and edema cause by diabetes, and can also treat or alleviate retinal microangioma, hemorrhage, exudation and special changes of veins in retinal vein occlusion and the like. The traditional Chinese medicine composition of the invention has comprehensive effect, low toxicity and side effect, and better therapeutic effectthan the existing medicine when used for treating fundus retinopathy, and has broad market prospect.

An application of garcinolic acid in preparing the medicines for suppressing the angiogenesis of tumor, arthritis, retinopathy, angioma and psoriasis and in turn treating them is disclosed.